Global Statistics

All countries
199,432,733
Confirmed
Updated on August 2, 2021 9:00 pm
All countries
178,201,889
Recovered
Updated on August 2, 2021 9:00 pm
All countries
4,246,057
Deaths
Updated on August 2, 2021 9:00 pm

COVID-19 Global Statistics

All countries
199,432,733
Confirmed
Updated on August 2, 2021 9:00 pm
All countries
178,201,889
Recovered
Updated on August 2, 2021 9:00 pm
All countries
4,246,057
Deaths
Updated on August 2, 2021 9:00 pm

Support Corruption-Free

Supporting Corruption-Free isn’t a transaction for an online service. Our Community is for people like you who care about a common good: ensuring that balanced, independent coverage of Nigeria and the world continues to be available to millions across the world, for free.

US Okays 1st Drug To Fight ‘Jewish’ Breast Cancer Gene

Israel Enables Christians to Celebrate Jesus’ Baptism Holiday Despite Coronavirus

Although the pandemic is keeping Christians and others from visiting the Holy Land, Israel is helping local Christians under lockdown celebrate their...

With 15 strokes of a pen, President Biden reverses Trump on climate, virus and immigration

US President Joe Biden moved swiftly to dismantle Donald Trump’s legacy on his first day in office, signing a series of executive...

Report: Former US President Plans to Flee the White House early

In the wake of yesterday's shocking riots and after finally admitting defeat in November's presidential election, Donald Trump - along with wife...

Larry King, hospitalized with COVID, moved out of ICU

LOS ANGELES — Veteran talk show host Larry King, suffering from COVID-19, has been moved out of the intensive care unit at...

America’s Fate To Be Decided in Two Days

Civil war or the will of the people? The events on two days in the next two weeks will...

US regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene, known as the “Jewish gene” because of its prevalence in Ashkenazi Jewish women.

The Food and Drug Administration on Friday approved AstraZeneca PLC’s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.

The drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA.

In the US, Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. The company is offering patients financial assistance.

“While there is currently no cure for metastatic breast cancer, today’s approval offers a new, targeted option that may help to delay disease progression for these patients,” Dr. Susan M. Domchek at the University of Pennsylvania’s Abramson Cancer Center said in a statement.

Until recently, cancer medicines targeted the disease based on where in the body it occurs.

This photo provided by AstraZeneca shows a bottle of Lynparza. (Courtesy of AstraZeneca via AP)

This is a new approach to “target the underlying genetic causes of a cancer,” the FDA’s Dr. Richard Pazdur said in a statement.

The agency also approved a companion blood test from Myriad Genetic Laboratories Inc. for detecting BRCA mutations and determining which patients likely would benefit from Lynparza.

About 250,000 people each year are diagnosed with breast cancer and just over 40,000 die from it, according to the National Cancer Institute. About 20 percent to 25 percent of patients with hereditary breast cancers have a BRCA mutation. BRCA-related breast cancer often strikes younger people and is harder to treat than other breast cancers.

Ashkenazi Jewish women are believed to be more susceptible to the mutation because of their limited gene pool.

Ashkenazi Jews in particular have a significantly higher risk for breast cancer: They are about three times as likely as non-Ashkenazim to carry mutations in the BRCA-1 and BRCA-2 genes that lead to a very high chance of developing cancer. One of the BRCA-1 mutations is associated with a 65% chance of developing breast cancer. Based on family history, including on the father’s side, the chances could be even higher.

The latest approval was based on a study of 302 women with cancers that have spread beyond the breast and who had a BRCA gene mutation.

Lynparza modestly delayed the time until cancer worsened — seven months versus four months for women given one of three commonly used chemotherapies. About half the study participants responded to Lynparza compared with about a quarter of those only treated with chemotherapy. It’s unknown whether treatment increases survival.

Possible side effects are less severe than for chemotherapy, but serious problems can include blood and bone marrow cancers. Common side effects include nausea, fatigue, respiratory infections and blood count problems.

Lynparza is marketed jointly by UK-based AstraZeneca and Merck & Co., which is based in Kenilworth, New Jersey.

Hot Topics

Israel Enables Christians to Celebrate Jesus’ Baptism Holiday Despite Coronavirus

Although the pandemic is keeping Christians and others from visiting the Holy Land, Israel is helping local Christians under lockdown celebrate their...

With 15 strokes of a pen, President Biden reverses Trump on climate, virus and immigration

US President Joe Biden moved swiftly to dismantle Donald Trump’s legacy on his first day in office, signing a series of executive...

Report: Former US President Plans to Flee the White House early

In the wake of yesterday's shocking riots and after finally admitting defeat in November's presidential election, Donald Trump - along with wife...

Related Articles

Israel Enables Christians to Celebrate Jesus’ Baptism Holiday Despite Coronavirus

Although the pandemic is keeping Christians and others from visiting the Holy Land, Israel is helping local Christians under lockdown celebrate their...

With 15 strokes of a pen, President Biden reverses Trump on climate, virus and immigration

US President Joe Biden moved swiftly to dismantle Donald Trump’s legacy on his first day in office, signing a series of executive...

Report: Former US President Plans to Flee the White House early

In the wake of yesterday's shocking riots and after finally admitting defeat in November's presidential election, Donald Trump - along with wife...